Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iNK004
- Development stage
- Preclinical
- Lead developer
- Guangzhou Ruixin Biotechnology
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
iNK004 is a chimeric antigen receptor (CAR)-engineered induced pluripotent stem cell (iPSC)-derived natural killer (NK) cell therapy developed by Cell Inspire Biotechnology. It is designed to target B-cell maturation antigen (BCMA), a protein highly expressed on the surface of malignant plasma cells in multiple myeloma. By utilizing iPSC technology, iNK004 aims to provide an "off-the-shelf" cellular immunotherapy that overcomes the limitations of patient-specific CAR-T therapies, such as manufacturing complexity and high costs. The CAR construct enables the iPSC-derived NK cells to specifically recognize and eliminate BCMA-expressing multiple myeloma cells.
02
Targets
BCMA (B-cell maturation antigen)iNKT TCR (Invariant natural killer T-cell receptor)
Beyond the preview
Go deeper on iNK004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iNK004.